The global hepatic encephalopathy treatment market garnered a market value of US$ 1486.39 Million in 2022 and is expected to accumulate a market value of US$ 2971.51 Million by registering a CAGR of 6.5% in the forecast period 2023 to 2033. The rise in the prevalence of liver diseases, including cirrhosis and non-alcoholic fatty liver disease (NAFLD), is a contributing factor to the growth of the market. The market for hepatic encephalopathy treatment registered a CAGR of 3.9% in the historical period 2018 to 2022
Hepatic encephalopathy (HE) treatment aims to manage the symptoms and underlying causes of the condition. HE is a condition where the liver is unable to remove toxins from the bloodstream effectively, leading to a buildup of toxins in the brain. The condition can range from mild to severe, with symptoms such as confusion, personality changes, tremors, and even coma.
The treatment of HE typically involves managing the underlying cause of the condition, such as liver disease or cirrhosis. This may involve treating the underlying liver disease or cirrhosis, such as through medication, diet, or lifestyle changes.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | US$ 1583 Million |
| Anticipated Forecast Value (2033) | US$ 2971.51 Million |
| Projected Growth Rate (2023 to 2033) | 6.5% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider Future Market Insights- the market for Hepatic encephalopathy treatment reflected a value of 3.9% during the historical period, 2018 to 2022.
During this period, there have been several advancements in the treatment of HE, particularly in the use of medications such as lactulose and rifaximin. These medications have been shown to be effective in managing the symptoms of HE and preventing complications.
In addition, there has been increased awareness of the importance of managing the underlying cause of HE, such as liver disease or cirrhosis, through medication, diet, or lifestyle changes. This approach aims to not only manage the symptoms of HE but also prevent its recurrence.
Furthermore, there have been ongoing clinical trials investigating new medications and treatment approaches for HE. For example, a study published in 2019 suggested that probiotics may be effective in reducing the risk of HE in patients with cirrhosis. Other studies have explored the use of novel medications, such as ammonia scavengers, in the treatment of HE.
Thus, the market for Hepatic encephalopathy treatment is expected to register a CAGR of 6.5% in the forecast period 2023 to 2033.
Prevalence of liver diseases driving market growth for hepatic encephalopathy treatment market
The rising incidence of liver diseases such as cirrhosis, hepatitis, and fatty liver disease is a significant driver of the HE treatment market. These conditions are major risk factors for the development of HE, and the increasing prevalence of liver diseases is expected to drive the demand for HE treatment.
As awareness of HE increases among patients and healthcare professionals, there is a growing emphasis on early diagnosis and treatment. This is expected to drive the demand for HE treatment. There have been several technological advancements in HE treatment, such as the development of new medications and therapies. For example, the use of lactulose and rifaximin has become the standard of care in the treatment of HE, and there is ongoing research into new medications and therapies.
As healthcare spending increases globally, there is a growing demand for effective and innovative treatments for liver diseases and HE. The elderly population is at an increased risk of developing liver diseases and HE, and the growing geriatric population is expected to drive the demand for HE treatment.
Availability of treatment for hepatic encephalopathy boosting market growth
Medications: There are several medications that can be used to treat HE, including lactulose, rifaximin, and neomycin. These medications work by reducing the levels of ammonia in the body, which can help alleviate symptoms of HE.
Dietary changes: A low-protein diet may be recommended for patients with HE, as protein is broken down into ammonia in the body. Eating smaller, more frequent meals can also help reduce the amount of ammonia produced.
Management of underlying liver disease: Treating the underlying liver disease that is causing HE is essential for managing the condition. This may involve medications to treat hepatitis, cirrhosis, or other liver conditions.
Elimination of potential triggers: In some cases, HE can be triggered by certain medications or substances. Eliminating these triggers can help reduce the severity of symptoms.
Transplantation: In severe cases of HE that do not respond to other treatments, liver transplantation may be recommended.
Principal Consultant
Limited treatment options along with high cost of treatment derailing progress of hepatic encephalopathy treatment market
One of the biggest challenges in the treatment of HE is the lack of early diagnosis. Many patients may not show symptoms until the disease has progressed to a more advanced stage, making early detection and treatment difficult.
While medications such as lactulose and rifaximin have been shown to be effective in managing HE symptoms, there are limited treatment options available. This leaves healthcare providers with few options for managing the condition, particularly in cases where patients do not respond to standard treatments.
The cost of HE treatment can be high, particularly in cases where patients require hospitalization or ongoing medication. This can be a significant barrier to access for some patients, particularly those with limited financial resources. While medications such as lactulose and rifaximin are generally well-tolerated, they can cause side effects such as diarrhea, nausea, and abdominal discomfort. This can be challenging for patients and may impact their quality of life.
Patients with HE often have other comorbidities, such as liver disease, diabetes, or heart disease, which can complicate treatment and increase the risk of adverse outcomes.
Presence of major key players and medications in the region contributing to market growth in North America
The North America Hepatic Encephalopathy (HE) treatment market is a significant contributor to the global HE treatment market. The market is primarily driven by the increasing prevalence of liver diseases, growing awareness of HE, and the availability of advanced treatment options.
The market is dominated by several key players, including Salix Pharmaceuticals (a subsidiary of Bausch Health Companies Inc.), Teva Pharmaceuticals, and Norgine B.V. These companies are investing in research and development activities to develop new treatment options and expand their product portfolio.
The increasing demand for lactulose and rifaximin, which are the standard of care for HE treatment, is expected to drive the market growth. The availability of these medications and the growing awareness of HE among healthcare professionals and patients are expected to contribute to the growth of the market.
Overall, the North America Hepatic Encephalopathy treatment market is expected to continue growing due to the increasing prevalence of liver diseases and growing awareness of HE. The availability of advanced treatment options and ongoing research and development activities are also expected to drive the market growth. Thus, North America is expected to possess 44% market share for hepatic encephalopathy (HE) treatment market in 2023.
Growing awareness of hepatic encephalopathy creating lucrative opportunities for Hepatic Encephalopathy in Europe
The prevalence of liver diseases, such as cirrhosis and hepatitis, is increasing in Europe, which is leading to a rise in the number of patients suffering from Hepatic Encephalopathy. There is a growing awareness of the condition among healthcare professionals, which is leading to earlier detection and diagnosis of Hepatic Encephalopathy.
The aging population in Europe is at a higher risk of developing liver disease, and thus Hepatic Encephalopathy, which is driving the market growth. The development of advanced diagnostic tools and therapies is also driving the growth of the Hepatic Encephalopathy treatment market in Europe.
With the increasing prevalence of liver disease and associated complications, there has been a rise in healthcare spending in Europe, which is driving the demand for effective treatments for Hepatic Encephalopathy. Governments in Europe are taking initiatives to improve access to healthcare services and treatments, which is also driving the market growth of Hepatic Encephalopathy treatment. Thus, Europe is expected to possess 39% market share for hepatic encephalopathy (HE) treatment market in 2023.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Access to advanced technologies making hospital pharmacies dependable for hepatic encephalopathy treatment
Hospital pharmacies are often the best choice for Hepatic Encephalopathy (HE) treatment because they have access to a wide range of medications and specialized resources that are needed to treat this condition effectively. HE is a complex condition that requires careful management and monitoring of medications and therapies to ensure optimal outcomes. Hospital pharmacies have specialized pharmacists who are trained to work closely with medical professionals to develop and implement individualized treatment plans for patients with HE.
Hospital pharmacies also have access to advanced technologies and medication delivery systems, which can be particularly important in treating HE. For example, some medications used to treat HE may need to be administered intravenously or through other specialized delivery methods that are only available in hospital settings.
In addition, hospital pharmacies are equipped to manage the unique needs of patients with HE who may be taking multiple medications or have other medical conditions that require careful coordination of care. This can help ensure that patients receive the best possible care and that their medications are managed safely and effectively. Thus, hospital pharmacies are expected to possess 49% market share for hepatic encephalopathy (HE) treatment market in 2023.
Key players in the hepatic encephalopathy treatment market are Mallinckrodt Pharmaceuticals, Salix Pharmaceuticals, GlaxoSmithKline plc., Pfizer Inc., ASKA Pharmaceutical Co., Ltd., Bausch Health, Johnson & Johnson Services, Inc., Janssen Global Services, Takeda Pharmaceutical Company Limited, Merck & Co., Inc.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 1583 Million |
| Market Value in 2033 | US$ 2971.51 Million |
| Growth Rate | CAGR of 6.5% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
The market is expected to record a CAGR of 6.5% through 2033.
The market registered a growth of 3.9% from 2018 to 2022.
The market is likely to reach US$ 1,583 million in 2023.
Key players are investing in research and development.
High treatment cost and limited treatment options pose a key challenge for the market.
1. Executive Summary | Hepatic Encephalopathy Treatment Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033
5.3.1. Antibiotics
5.3.2. Laxatives
5.3.3. L-ornithine
5.3.4. L-aspartate
5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Diagnosis
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Diagnosis, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Diagnosis, 2023 to 2033
6.3.1. Blood Tests
6.3.2. CT Scan
6.3.3. Liver Functioning Tests
6.4. Y-o-Y Growth Trend Analysis By Diagnosis, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Diagnosis, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration , 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration , 2023 to 2033
7.3.1. Oral
7.3.2. Injectable
7.3.3. Intravenous
7.3.4. Others
7.4. Y-o-Y Growth Trend Analysis By Route of Administration , 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Route of Administration , 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022
8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033
8.3.1. Hospital Pharmacy
8.3.2. Online Pharmacy
8.3.3. Retail Pharmacy
8.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022
8.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033
9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
9.1. Introduction
9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
9.3.1. North America
9.3.2. Latin America
9.3.3. Europe
9.3.4. South Asia
9.3.5. East Asia
9.3.6. Oceania
9.3.7. MEA
9.4. Market Attractiveness Analysis By Region
10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. U.S.
10.2.1.2. Canada
10.2.2. By Drug Class
10.2.3. By Diagnosis
10.2.4. By Route of Administration
10.2.5. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug Class
10.3.3. By Diagnosis
10.3.4. By Route of Administration
10.3.5. By Distribution Channel
10.4. Key Takeaways
11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Brazil
11.2.1.2. Mexico
11.2.1.3. Rest of Latin America
11.2.2. By Drug Class
11.2.3. By Diagnosis
11.2.4. By Route of Administration
11.2.5. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug Class
11.3.3. By Diagnosis
11.3.4. By Route of Administration
11.3.5. By Distribution Channel
11.4. Key Takeaways
12. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. Germany
12.2.1.2. U.K.
12.2.1.3. France
12.2.1.4. Spain
12.2.1.5. Italy
12.2.1.6. Rest of Europe
12.2.2. By Drug Class
12.2.3. By Diagnosis
12.2.4. By Route of Administration
12.2.5. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug Class
12.3.3. By Diagnosis
12.3.4. By Route of Administration
12.3.5. By Distribution Channel
12.4. Key Takeaways
13. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. India
13.2.1.2. Malaysia
13.2.1.3. Singapore
13.2.1.4. Thailand
13.2.1.5. Rest of South Asia
13.2.2. By Drug Class
13.2.3. By Diagnosis
13.2.4. By Route of Administration
13.2.5. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Drug Class
13.3.3. By Diagnosis
13.3.4. By Route of Administration
13.3.5. By Distribution Channel
13.4. Key Takeaways
14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. China
14.2.1.2. Japan
14.2.1.3. South Korea
14.2.2. By Drug Class
14.2.3. By Diagnosis
14.2.4. By Route of Administration
14.2.5. By Distribution Channel
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Drug Class
14.3.3. By Diagnosis
14.3.4. By Route of Administration
14.3.5. By Distribution Channel
14.4. Key Takeaways
15. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. Australia
15.2.1.2. New Zealand
15.2.2. By Drug Class
15.2.3. By Diagnosis
15.2.4. By Route of Administration
15.2.5. By Distribution Channel
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Drug Class
15.3.3. By Diagnosis
15.3.4. By Route of Administration
15.3.5. By Distribution Channel
15.4. Key Takeaways
16. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
16.2.1. By Country
16.2.1.1. GCC Countries
16.2.1.2. South Africa
16.2.1.3. Israel
16.2.1.4. Rest of MEA
16.2.2. By Drug Class
16.2.3. By Diagnosis
16.2.4. By Route of Administration
16.2.5. By Distribution Channel
16.3. Market Attractiveness Analysis
16.3.1. By Country
16.3.2. By Drug Class
16.3.3. By Diagnosis
16.3.4. By Route of Administration
16.3.5. By Distribution Channel
16.4. Key Takeaways
17. Key Countries Market Analysis
17.1. U.S.
17.1.1. Pricing Analysis
17.1.2. Market Share Analysis, 2022
17.1.2.1. By Drug Class
17.1.2.2. By Diagnosis
17.1.2.3. By Route of Administration
17.1.2.4. By Distribution Channel
17.2. Canada
17.2.1. Pricing Analysis
17.2.2. Market Share Analysis, 2022
17.2.2.1. By Drug Class
17.2.2.2. By Diagnosis
17.2.2.3. By Route of Administration
17.2.2.4. By Distribution Channel
17.3. Brazil
17.3.1. Pricing Analysis
17.3.2. Market Share Analysis, 2022
17.3.2.1. By Drug Class
17.3.2.2. By Diagnosis
17.3.2.3. By Route of Administration
17.3.2.4. By Distribution Channel
17.4. Mexico
17.4.1. Pricing Analysis
17.4.2. Market Share Analysis, 2022
17.4.2.1. By Drug Class
17.4.2.2. By Diagnosis
17.4.2.3. By Route of Administration
17.4.2.4. By Distribution Channel
17.5. Germany
17.5.1. Pricing Analysis
17.5.2. Market Share Analysis, 2022
17.5.2.1. By Drug Class
17.5.2.2. By Diagnosis
17.5.2.3. By Route of Administration
17.5.2.4. By Distribution Channel
17.6. U.K.
17.6.1. Pricing Analysis
17.6.2. Market Share Analysis, 2022
17.6.2.1. By Drug Class
17.6.2.2. By Diagnosis
17.6.2.3. By Route of Administration
17.6.2.4. By Distribution Channel
17.7. France
17.7.1. Pricing Analysis
17.7.2. Market Share Analysis, 2022
17.7.2.1. By Drug Class
17.7.2.2. By Diagnosis
17.7.2.3. By Route of Administration
17.7.2.4. By Distribution Channel
17.8. Spain
17.8.1. Pricing Analysis
17.8.2. Market Share Analysis, 2022
17.8.2.1. By Drug Class
17.8.2.2. By Diagnosis
17.8.2.3. By Route of Administration
17.8.2.4. By Distribution Channel
17.9. Italy
17.9.1. Pricing Analysis
17.9.2. Market Share Analysis, 2022
17.9.2.1. By Drug Class
17.9.2.2. By Diagnosis
17.9.2.3. By Route of Administration
17.9.2.4. By Distribution Channel
17.10. India
17.10.1. Pricing Analysis
17.10.2. Market Share Analysis, 2022
17.10.2.1. By Drug Class
17.10.2.2. By Diagnosis
17.10.2.3. By Route of Administration
17.10.2.4. By Distribution Channel
17.11. Malaysia
17.11.1. Pricing Analysis
17.11.2. Market Share Analysis, 2022
17.11.2.1. By Drug Class
17.11.2.2. By Diagnosis
17.11.2.3. By Route of Administration
17.11.2.4. By Distribution Channel
17.12. Singapore
17.12.1. Pricing Analysis
17.12.2. Market Share Analysis, 2022
17.12.2.1. By Drug Class
17.12.2.2. By Diagnosis
17.12.2.3. By Route of Administration
17.12.2.4. By Distribution Channel
17.13. Thailand
17.13.1. Pricing Analysis
17.13.2. Market Share Analysis, 2022
17.13.2.1. By Drug Class
17.13.2.2. By Diagnosis
17.13.2.3. By Route of Administration
17.13.2.4. By Distribution Channel
17.14. China
17.14.1. Pricing Analysis
17.14.2. Market Share Analysis, 2022
17.14.2.1. By Drug Class
17.14.2.2. By Diagnosis
17.14.2.3. By Route of Administration
17.14.2.4. By Distribution Channel
17.15. Japan
17.15.1. Pricing Analysis
17.15.2. Market Share Analysis, 2022
17.15.2.1. By Drug Class
17.15.2.2. By Diagnosis
17.15.2.3. By Route of Administration
17.15.2.4. By Distribution Channel
17.16. South Korea
17.16.1. Pricing Analysis
17.16.2. Market Share Analysis, 2022
17.16.2.1. By Drug Class
17.16.2.2. By Diagnosis
17.16.2.3. By Route of Administration
17.16.2.4. By Distribution Channel
17.17. Australia
17.17.1. Pricing Analysis
17.17.2. Market Share Analysis, 2022
17.17.2.1. By Drug Class
17.17.2.2. By Diagnosis
17.17.2.3. By Route of Administration
17.17.2.4. By Distribution Channel
17.18. New Zealand
17.18.1. Pricing Analysis
17.18.2. Market Share Analysis, 2022
17.18.2.1. By Drug Class
17.18.2.2. By Diagnosis
17.18.2.3. By Route of Administration
17.18.2.4. By Distribution Channel
17.19. GCC Countries
17.19.1. Pricing Analysis
17.19.2. Market Share Analysis, 2022
17.19.2.1. By Drug Class
17.19.2.2. By Diagnosis
17.19.2.3. By Route of Administration
17.19.2.4. By Distribution Channel
17.20. South Africa
17.20.1. Pricing Analysis
17.20.2. Market Share Analysis, 2022
17.20.2.1. By Drug Class
17.20.2.2. By Diagnosis
17.20.2.3. By Route of Administration
17.20.2.4. By Distribution Channel
17.21. Israel
17.21.1. Pricing Analysis
17.21.2. Market Share Analysis, 2022
17.21.2.1. By Drug Class
17.21.2.2. By Diagnosis
17.21.2.3. By Route of Administration
17.21.2.4. By Distribution Channel
18. Market Structure Analysis
18.1. Competition Dashboard
18.2. Competition Benchmarking
18.3. Market Share Analysis of Top Players
18.3.1. By Regional
18.3.2. By Drug Class
18.3.3. By Diagnosis
18.3.4. By Route of Administration
18.3.5. By Distribution Channel
19. Competition Analysis
19.1. Competition Deep Dive
19.1.1. Mallinckrodt Pharmaceuticals
19.1.1.1. Overview
19.1.1.2. Product Portfolio
19.1.1.3. Profitability by Market Segments
19.1.1.4. Sales Footprint
19.1.1.5. Strategy Overview
19.1.1.5.1. Marketing Strategy
19.1.2. Salix Pharmaceuticals
19.1.2.1. Overview
19.1.2.2. Product Portfolio
19.1.2.3. Profitability by Market Segments
19.1.2.4. Sales Footprint
19.1.2.5. Strategy Overview
19.1.2.5.1. Marketing Strategy
19.1.3. GlaxoSmithKline plc.
19.1.3.1. Overview
19.1.3.2. Product Portfolio
19.1.3.3. Profitability by Market Segments
19.1.3.4. Sales Footprint
19.1.3.5. Strategy Overview
19.1.3.5.1. Marketing Strategy
19.1.4. Pfizer Inc.
19.1.4.1. Overview
19.1.4.2. Product Portfolio
19.1.4.3. Profitability by Market Segments
19.1.4.4. Sales Footprint
19.1.4.5. Strategy Overview
19.1.4.5.1. Marketing Strategy
19.1.5. ASKA Pharmaceutical Co., Ltd.
19.1.5.1. Overview
19.1.5.2. Product Portfolio
19.1.5.3. Profitability by Market Segments
19.1.5.4. Sales Footprint
19.1.5.5. Strategy Overview
19.1.5.5.1. Marketing Strategy
19.1.6. Bausch Health
19.1.6.1. Overview
19.1.6.2. Product Portfolio
19.1.6.3. Profitability by Market Segments
19.1.6.4. Sales Footprint
19.1.6.5. Strategy Overview
19.1.6.5.1. Marketing Strategy
19.1.7. Johnson & Johnson Services, Inc.
19.1.7.1. Overview
19.1.7.2. Product Portfolio
19.1.7.3. Profitability by Market Segments
19.1.7.4. Sales Footprint
19.1.7.5. Strategy Overview
19.1.7.5.1. Marketing Strategy
19.1.8. Janssen Global Services
19.1.8.1. Overview
19.1.8.2. Product Portfolio
19.1.8.3. Profitability by Market Segments
19.1.8.4. Sales Footprint
19.1.8.5. Strategy Overview
19.1.8.5.1. Marketing Strategy
19.1.9. Takeda Pharmaceutical Company Limited
19.1.9.1. Overview
19.1.9.2. Product Portfolio
19.1.9.3. Profitability by Market Segments
19.1.9.4. Sales Footprint
19.1.9.5. Strategy Overview
19.1.9.5.1. Marketing Strategy
19.1.10. Merck & Co., Inc.
19.1.10.1. Overview
19.1.10.2. Product Portfolio
19.1.10.3. Profitability by Market Segments
19.1.10.4. Sales Footprint
19.1.10.5. Strategy Overview
19.1.10.5.1. Marketing Strategy
20. Assumptions & Acronyms Used
21. Research Methodology
Explore Healthcare Insights
View Reports
Hepatic Encephalopathy Treatment Market
